 "drugs, pharma sector")
Natco Pharma share price: Pharmaceutical company Natco Pharma share price rose as much as 6.66 per cent to hit an intraday high of ₹919.90 per share.
However, by 12:01 PM, Natco Pharma share price was off day’s high, and was trading 2.48 per cent higher at ₹883.80 per share. In comparison, BSE Sensex was trading flat with a negative bias at 81,287.30 level.
Why did Natco Pharma share price rise in trade today?
Natco Pharma share price rose on the back of a healthy March quarter of financial year 2025 (Q4FY25) results.
The pharma company’s consolidated profit after tax (PAT) rose to ₹406 crore in the March quarter of FY25, from ₹386.3 crore in the March quarter of FY24.
The company’s revenue from operations, or topline, surged to ₹1,287.3 crore in Q4FY25, from ₹1,110.3 crore in Q4FY24.
ALSO READ: Blue Water Logistics IPO | Aegis Vopak Terminals IPO | Prostarm Info Systems IPO ends today
Also Read
 "Market, BSE, NSE, NIfty, Stock Market, investment")
 "Amid policy movements on India's lofty shipbuilding targets, the Ministry of Ports, Shipping and Waterways (ShipMin) on Friday deliberated with coastal states during the 20th Maritime State Development Council (MSDC) meeting on the possibility of est")
 "stock market trading")
 "Stock market")
 "Indian shrimp sector crisis, US tariffs on shrimp exports, shrimp export losses India, $1 billion shrimp loss, vannamei shrimp exports, 50 count shrimp price drop, farm-gate shrimp prices India, Rs 70/kg shrimp price fall, Indian seafood export impac")
At the operating level, earnings before interest, tax, depreciation and amortisation (Ebitda) soared to ₹614.4 crore in the March quarter of FY25, from ₹539.3 crore in the March quarter of FY24. However, Ebitda margin squeezed to 47.7 per cent in Q4FY25, from 48.6 per cent a year ago.
About Natco Pharma
Natco Pharma is a Hyderabad-based pharmaceutical company engaged in the development, manufacturing, and distribution of both generic and branded drugs.
The company also operates in the specialty pharmaceutical and crop protection segments. Known for its strong focus on research and development, the company is a science-driven organisation with a leadership position in oncology, particularly in targeted therapies within the Indian market.
In the United States, it concentrates on launching complex and limited-competition molecules.
The company operates nine manufacturing facilities and two research and development (R&D) centres across India.
Its production sites are accredited by major global regulatory agencies, including the US FDA, Brazil's ANVISA, Health Canada, and the World Health Organization (WHO), among others. Through its extensive compliance and quality framework, Natco Pharma serves over 50 international markets, reinforcing its global footprint in the pharmaceutical sector.
 "market, stocks, stock market trading, stock market")
 "share market, stock market")
 "NSE")
 "ipo market listing share market")
 "markets")
